(VIANEWS) – The NASDAQ ended the session with Illumina (ILMN) jumping 8.22% to $210.85 on Wednesday while NASDAQ rose 0.41% to $12,431.53.
Illumina, Inc. offers array-based and sequencing solutions for genomic and genetic analysis. Illumina’s services and products are available to customers across a variety of markets. They enable the use of genomic solutions for research and clinical applications. These include the areas of life science, oncology and reproductive health. It offers consumables and instruments for genetic analysis, genotyping, sequencing, contract service contracts, development and licensing agreements as well as services in cancer detection and testing. Customers include academic and government institutions as well as hospitals and pharmaceutical and biotechnology companies. It sells directly to its customers in North America and Europe as well as Latin America and the Asia-Pacific. It was founded in 1998 in San Diego, California.
Today’s last reported volume for Illumina is 2061220, 35.13% above its average volume of 1525350.
Illumina’s last close was $194.84, 60.42% under its 52-week high of $492.29.
The company’s growth estimates for the current quarter and the next is a negative 65.2% and a negative 22.8%, respectively.
Year-on-year quarterly revenue growth grew by 3.2%, now sitting on 4.69B for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
Illumina’s stock is considered to be overbought (>=80).
Illumina’s Stock Yearly Top and Bottom Value
Illumina’s stock is valued at $210.85 at 18:38 EST, way below its 52-week high of $492.29 and way higher than its 52-week low of $173.45.
Illumina’s Moving Average
Illumina’s value is above its 50-day moving average of $201.92 and way under its 200-day moving average of $302.85.
More news about Illumina (ILMN).